Alembic Pharmaceuticals Ltd

Ipca is the biggest producer of the drug. Cadila Healthcare, based in Ahmedabad, too is a major player

Vadodara headquartered Alembic Pharmaceuticals Ltd reported a 52 per cent year on year (YoY) rise in net profit for the third quarter of the 2017-18 fiscal to Rs 1.3 billion riding on the back of a 14 per cent yoy growth in the India formulations business while the US generics business saw flat growth. The company's consolidated net sales for the quarter stood at Rs 8.4 bn, up 8 per cent YoY, while the Ebitda margin came in at 22 per cent compared to 19 per cent in the same quarter last year. Pranav Amin, managing director, Alembic Pharmaceuticals said that the India branded business recovered showing a good growth. "The US generics business continues to do well as we pick up market share leading to higher volumes. Aleor, our joint venture for dermatology products, filed its first abbreviated new drug application (ANDA)." During the quarter under review, the company's international generics business posted revenues of Rs 3.1 bn as against Rs 3 bn in the corresponding quarter last ...

The company's net sales also dipped by 13.5 per cent to Rs 879 crore for the quarter under review